Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: Hillhouse Capital Management, Ltd. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Convertible Preferred Stock	$		Common Stock (2098581)		Indirect

Footnotes

F1: Each share of Series D Convertible Preferred Stock is convertible, at the option of the holder thereof, at any time and from time to time into shares of the Issuer's common stock, $0.0001 par value ("Common Stock"). In addition, Series D Convertible Preferred Stock will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F2: The Series D Convertible Preferred Stock has no expiration date.

F3: The Series D Convertible Preferred Stock converts into Common Stock on a 2.133-for-1 basis into the number of shares of Common Stock shown in column 3.

F4: The securities to which this filing relates are held directly by Hillhouse WHP Holdings Limited, a company incorporated under the laws of the British Virgin Islands ("WHP"). WHP is owned by Hillhouse Fund II, L.P., a Cayman Islands limited partnership ("Fund II"). Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person"), acts as the sole management company of Fund II. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by WHP. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.